Laboratory of Metabolism and Obesity, Vall d'Hebron - Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain.
Group of Mitochondrial and Neuromuscular Pathology, Vall d'Hebron - Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain; CIBERER, CIBER on Rare Diseases, Instituto de Salud Carlos III, Barcelona, Spain.
Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1298-1312. doi: 10.1016/j.bbadis.2019.01.025. Epub 2019 Jan 26.
In humans, low brown adipose tissue (BAT) mass and activity have been associated with increased adiposity and fasting glucose levels, suggesting that defective BAT-dependent thermogenesis could contribute to the development of obesity and/or type 2 diabetes. The thermogenic function of BAT relies on a vast network of mitochondria exclusively equipped with UCP1. Mitochondrial biogenesis is exquisitely regulated by a well-defined network of transcription factors that coordinate the expression of nuclear genes required for the formation of functional mitochondria. However, less is known about the mitochondrial factors that control the expression of the genes encoded by the mitochondrial genome. Here, we have studied the role of mitochondrial transcription termination factor-4 (MTERF4) in BAT by using a new mouse model devoid of MTERF4 specifically in adipocytes (MTERF4-FAT-KO mice). Lack of MTERF4 in BAT leads to reduced OxPhos mitochondrial protein levels and impaired assembly of OxPhos complexes I, III and IV due to deficient translation of mtDNA-encoded proteins. As a result, brown adipocytes lacking MTERF4 exhibit impaired respiratory capacity. MTERF4-FAT-KO mice show a blunted thermogenic response and are unable to maintain body temperature when exposed to cold. Despite impaired BAT function, MTERF4-FAT-KO mice do not develop obesity or insulin resistance. Still, MTERF4-FAT-KO mice became resistant to the insulin-sensitizing effects of β-specific adrenergic receptor agonists. Our results demonstrate that MTERF4 regulates mitochondrial protein translation and is essential for proper BAT thermogenic activity. Our study also supports the notion that pharmacological activation of BAT is a plausible therapeutic target for the treatment of insulin resistance.
在人类中,低棕色脂肪组织(BAT)的质量和活性与肥胖和空腹血糖水平的增加有关,这表明有缺陷的 BAT 依赖性产热可能导致肥胖和/或 2 型糖尿病的发展。BAT 的产热功能依赖于一个庞大的线粒体网络,这些线粒体专门配备有 UCP1。线粒体生物发生受到一个明确的转录因子网络的精细调控,该网络协调了形成功能性线粒体所需的核基因的表达。然而,对于控制线粒体基因组编码基因表达的线粒体因子知之甚少。在这里,我们通过使用一种新的缺乏脂肪细胞特异性 MTERF4 的小鼠模型(MTERF4-FAT-KO 小鼠)研究了线粒体转录终止因子-4(MTERF4)在 BAT 中的作用。BAT 中缺乏 MTERF4 会导致 OxPhos 线粒体蛋白水平降低,OxPhos 复合物 I、III 和 IV 的组装受损,这是由于 mtDNA 编码蛋白的翻译缺陷。结果,缺乏 MTERF4 的棕色脂肪细胞表现出呼吸能力受损。MTERF4-FAT-KO 小鼠表现出产热反应迟钝,当暴露于寒冷时无法维持体温。尽管 BAT 功能受损,但 MTERF4-FAT-KO 小鼠不会发展为肥胖或胰岛素抵抗。尽管如此,MTERF4-FAT-KO 小鼠对 β 特异性肾上腺素能受体激动剂的胰岛素增敏作用产生抗性。我们的结果表明,MTERF4 调节线粒体蛋白翻译,是适当的 BAT 产热活性所必需的。我们的研究还支持这样一种观点,即 BAT 的药理学激活是治疗胰岛素抵抗的合理治疗靶点。